Charles River Laboratories International Inc. (CRL) Social Stream
CHARLES RIVER LABORATORIES INTERNATIONAL INC (CRL) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering CHARLES RIVER LABORATORIES INTERNATIONAL INC.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-04 | 9 | $465 | $324 | $418 | $223.35 | 87.15% |
| 2021-11-16 | 9 | $465 | $324 | $424.111 | $223.35 | 89.89% |
| 2022-01-20 | 8 | $465 | $324 | $424.111 | $223.35 | 89.89% |
| 2022-03-15 | 9 | $465 | $324 | $396.555 | $223.35 | 77.55% |
| 2022-04-06 | 9 | $465 | $350 | $405.625 | $223.35 | 81.61% |
| 2022-04-13 | 10 | $465 | $350 | $402.444 | $223.35 | 80.19% |
| 2022-04-25 | 10 | $465 | $280 | $392.444 | $223.35 | 75.71% |
| 2022-05-10 | 10 | $465 | $280 | $359.111 | $223.35 | 60.78% |
| 2022-06-09 | 11 | $465 | $280 | $351.666 | $223.35 | 57.45% |
| 2022-07-19 | 11 | $465 | $255 | $340.555 | $223.35 | 52.48% |
| 2022-07-27 | 11 | $465 | $255 | $338.333 | $223.35 | 51.48% |
| 2022-08-01 | 10 | $465 | $255 | $342.5 | $223.35 | 53.35% |
| 2022-08-05 | 10 | $465 | $230 | $310.625 | $223.35 | 39.08% |
| 2022-08-13 | 10 | $465 | $230 | $308.125 | $223.35 | 37.96% |
| 2022-08-16 | 11 | $400 | $230 | $287.5 | $223.35 | 28.72% |
| 2022-09-17 | 10 | $400 | $230 | $286.25 | $223.35 | 28.16% |
| 2022-10-17 | 10 | $400 | $240 | $287.5 | $223.35 | 28.72% |
| 2022-11-01 | 10 | $400 | $240 | $286.25 | $223.35 | 28.16% |
| 2022-11-03 | 10 | $400 | $240 | $282 | $223.35 | 26.26% |
| 2023-01-11 | 11 | $400 | $241 | $283.444 | $223.35 | 26.91% |
| 2023-01-27 | 11 | $400 | $233 | $281.555 | $223.35 | 26.06% |
| 2023-02-08 | 11 | $400 | $233 | $281 | $223.35 | 25.81% |
| 2023-03-01 | 11 | $300 | $230 | $259.8 | $223.35 | 16.32% |
| 2023-04-10 | 11 | $300 | $203 | $256.8 | $223.35 | 14.98% |
| 2023-05-11 | 11 | $300 | $203 | $255.3 | $223.35 | 14.3% |
| 2023-05-12 | 11 | $285 | $205 | $252.5 | $223.35 | 13.05% |
| 2023-06-06 | 11 | $285 | $205 | $249 | $223.35 | 11.48% |
| 2023-07-10 | 11 | $285 | $205 | $245.5 | $223.35 | 9.92% |
| 2023-08-09 | 11 | $285 | $205 | $244.5 | $223.35 | 9.47% |
| 2023-08-11 | 11 | $285 | $207 | $246.7 | $223.35 | 10.45% |
| 2023-09-12 | 11 | $285 | $207 | $249.2 | $223.35 | 11.57% |
| 2023-09-13 | 12 | $285 | $207 | $249.2 | $223.35 | 11.57% |
| 2023-09-20 | 12 | $285 | $207 | $245.818 | $223.35 | 10.06% |
| 2023-09-22 | 12 | $285 | $207 | $244.909 | $223.35 | 9.65% |
| 2023-09-25 | 12 | $285 | $207 | $244.454 | $223.35 | 9.45% |
| 2023-09-26 | 12 | $285 | $207 | $241.727 | $223.35 | 8.23% |
| 2023-10-13 | 12 | $275 | $207 | $237.09 | $223.35 | 6.15% |
| 2023-10-24 | 12 | $275 | $207 | $236.083 | $223.35 | 5.7% |
| 2023-11-08 | 12 | $275 | $207 | $234.833 | $223.35 | 5.14% |
| 2023-11-10 | 13 | $275 | $190 | $227.25 | $223.35 | 1.75% |
| 2023-11-13 | 13 | $275 | $189 | $222.538 | $223.35 | -0.36% |
| 2023-12-06 | 13 | $260 | $189 | $218.692 | $223.35 | -2.09% |
| 2023-12-12 | 13 | $256 | $189 | $217.153 | $223.35 | -2.77% |
| 2023-12-18 | 13 | $256 | $189 | $220.23 | $223.35 | -1.4% |
| 2023-12-20 | 13 | $256 | $189 | $222.538 | $223.35 | -0.36% |
| 2023-12-29 | 13 | $270 | $189 | $227.153 | $223.35 | 1.7% |
The Trend in the Analyst Price Target
Over the past 13 months, CRL's average price target has gone down $56.1.
CRL reports an average of 18.9% for its upside potential over the past 51 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-08-28 | 11 | 285 | 207 | 249.200 | 198.76 | 25.38% |
| 2023-09-06 | 11 | 285 | 207 | 249.200 | 204.44 | 21.89% |
| 2023-09-18 | 12 | 285 | 207 | 245.818 | 210.57 | 16.74% |
| 2023-11-03 | 12 | 275 | 207 | 234.833 | 181.91 | 29.09% |
| 2023-11-21 | 13 | 260 | 189 | 218.692 | 192.25 | 13.75% |
CRL Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.62 | 9 | 0 | 4 | 0 | 0 | 13 |
The Trend in the Broker Recommendations
Over the past 47 months, CRL's average broker recommendation rating improved by 0.32.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for CRL as an investment opportunity.
- In terms of how CHARLES RIVER LABORATORIES INTERNATIONAL INC fares relative to all US stocks, note that its average analyst price target is higher than 5056.65% of that group.
- In the context of Healthcare stocks, CHARLES RIVER LABORATORIES INTERNATIONAL INC's upside potential (average analyst target price relative to current price) is higher than 1590.06% of them.
- To contextualize these metrics, consider that out of stocks in the large market cap category, CHARLES RIVER LABORATORIES INTERNATIONAL INC's variance in analysts' estimates is lower than -2366.7% of them.
- To contextualize these metrics, consider that out of Healthcare stocks, CHARLES RIVER LABORATORIES INTERNATIONAL INC's number of analysts covering the stock is higher than 3736.18% of them.
In the Business Services industry, INCY, WSC, and ALLE are the three stocks most similar to CHARLES RIVER LABORATORIES INTERNATIONAL INC regarding the price target and analyst recommendation information presented here.
View All Top Stocks by Price Target
Is CRL a Buy, Hold or Sell? See the POWR Ratings now!